Correspondence
Breakthrough Zygomycosis after Voriconazole Treatment in Recipients of Hematopoietic Stem-Cell Transplants
N Engl J Med 2004; 350:950-952February 26, 2004
- Article
To the Editor:
The Food and Drug Administration (FDA) approved voriconazole for the treatment of invasive aspergillosis partly on the basis of data published in a report in the Journal, 1 which showed an improved clinical response and improved survival with voriconazole treatment as compared with a strategy of initial treatment with amphotericin B deoxycholate. In patients with neutropenia and persistent fever, the use of voriconazole as empirical therapy failed to fulfill criteria for noninferiority as compared with liposomal amphotericin B,2 and the results of that trial generated substantial discussion after the FDA declined approval of the drug for that indication.3 Nevertheless, the use of voriconazole has become common in the management of neutropenia and persistent fever, in the treatment of high-risk patients with pneumonia, and as prophylaxis in patients who are at risk for the development of invasive fungal infections. These uses of voriconazole are probably attributable to its lower overall toxicity, its ease of oral administration, and its broad antifungal spectrum, especially against aspergillus species.
Since September 2002, when voriconazole became available at our institution, we have noted an increased frequency of cases of zygomycosis among recipients of allogeneic hematopoietic stem-cell transplants. From September 2002 to June 2003, 124 patients underwent hematopoietic stem-cell transplantation. During this period, zygomycosis was diagnosed in four patients on the basis of pathological or mycologic identification (Table 1Table 1
Characteristics of Patients with Breakthrough Zygomycosis.). The diagnosis was made a median of 125 days after transplantation. All patients had received a diagnosis of graft-versus-host disease and were receiving treatment for it. Voriconazole was being given to three patients as antifungal prophylaxis and to one as empirical treatment for pulmonary nodules for a median of 36 days (range, 21 to 99) before diagnosis and a median of 20 days (range, 0 to 94) before the onset of symptoms that led to the diagnosis of zygomycosis. Initially, clinicians did not consider breakthrough or resistant invasive fungal infections. During the preceding 32 months, 370 patients underwent hematopoietic stem-cell transplantation, and only 2 had documented zygomycosis (4 cases in 119.6 patient-years, vs. 2 cases in 282.6 patient-years after hematopoietic stem-cell transplantation; unadjusted rate ratio, 4.73; 95 percent confidence interval, 0.87 to 25.8). There was no clustering of cases, and no zygomycetes were isolated from samples obtained during hospital environmental surveillance.Zygomycetes are resistant to voriconazole in vitro.4 Thus, selective pressure from prolonged use of voriconazole or increased survival among profoundly immunosuppressed patients may explain the increased frequency of zygomycosis among patients who remain at high risk for invasive fungal infections. This observation underscores the need to make an etiologic diagnosis of such infections, to consider resistant pathogens promptly, and to consider the risks, benefits, and tradeoffs5 of prophylactic therapy carefully.
5 ReferencesFrancisco M. Marty, M.D.
Lisa A. Cosimi, M.D.
Brigham and Women's Hospital, Boston, MA 02115
fmarty@partners.org Lindsey R. Baden, M.D.
1
Herbrecht R ,Denning DW ,Patterson TF , et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-415
Full Text | Web of Science | Medline2
Walsh TJ ,Pappas P ,Winston DJ , et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002;346:225-234
Full Text | Web of Science | Medline3
Powers JH ,Dixon CA ,Goldberger MJ . Voriconazole versus liposomal amphotericin B in patients with neutropenia and persistent fever. N Engl J Med 2002;346:289-290
Full Text | Web of Science | Medline4
Sun QN ,Fothergill AW ,McCarthy DI ,Rinaldi MG ,Graybill JR . In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002;46:1581-1582
CrossRef | Web of Science | Medline5
Marr KA . Empirical antifungal therapy -- new options, new tradeoffs. N Engl J Med 2002;346:278-280
Full Text | Web of Science | Medline
- Citing Articles (152)
Citing Articles
1
G. Petrikkos, A. Skiada, O. Lortholary, E. Roilides, T. J. Walsh, D. P. Kontoyiannis. (2012) Epidemiology and Clinical Manifestations of Mucormycosis. Clinical Infectious Diseases 54:suppl 1, S23-S34
CrossRef2
A. S. Ibrahim, B. Spellberg, T. J. Walsh, D. P. Kontoyiannis. (2012) Pathogenesis of Mucormycosis. Clinical Infectious Diseases 54:suppl 1, S16-S22
CrossRef3
Dimitrios P. Kontoyiannis. (2012) Invasive Mycoses: Strategies for Effective Management. The American Journal of Medicine 125:1, S25-S38
CrossRef4
John R. Perfect. (2012) The Impact of the Host on Fungal Infections. The American Journal of Medicine 125:1, S39-S51
CrossRef5
A. Skiada, L. Pagano, A. Groll, S. Zimmerli, B. Dupont, K. Lagrou, C. Lass-Florl, E. Bouza, N. Klimko, P. Gaustad, M. Richardson, P. Hamal, M. Akova, J. F. Meis, J.-L. Rodriguez-Tudela, E. Roilides, A. Mitrousia-Ziouva, G. Petrikkos, . (2011) Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clinical Microbiology and Infection 17:12, 1859-1867
CrossRef6
Sushil Mandhaniya, Chetanya Swaroop, Sanjay Thulkar, Sreenivas Vishnubhatla, Sushil K. Kabra, Immaculata Xess, Sameer Bakhshi. (2011) Oral Voriconazole Versus Intravenous Low Dose Amphotericin B for Primary Antifungal Prophylaxis in Pediatric Acute Leukemia Induction. Journal of Pediatric Hematology/Oncology 33:8, e333-e341
CrossRef7
Marisa H. Miceli, Samuel A. Lee. (2011) Emerging moulds: epidemiological trends and antifungal resistance. Mycoses 54:6, e666-e678
CrossRef8
Corrado Girmenia, Erica Finolezzi. (2011) New-generation triazole antifungal drugs: review of the Phase II and III trials. Clinical Investigation 1:11, 1577-1594
CrossRef9
2011. Mucormycosis. , 431-455.
CrossRef10
Priya A. Prasad, Ana M. Vaughan, Theoklis E. Zaoutis. (2011) Trends in zygomycosis in children. Mycosesno-no
CrossRef11
Eloisa Llata, David B. Blossom, H. Jean Khoury, Carol Y. Rao, Kathleen A. Wannemuehler, Judith Noble-Wang, Amelia A. Langston, Bruce S. Ribner, G. Marshall Lyon, Kathryn E. Arnold, Deonne R. Jackson, Mary E. Brandt, Tom M. Chiller, S. Arunmozhi Balajee, Arjun Srinivasan, Shelley S. Magill. (2011) A cluster of mucormycosis infections in hematology patients: challenges in investigation and control of invasive mold infections in high-risk patient populations. Diagnostic Microbiology and Infectious Disease 71:1, 72-80
CrossRef12
Sanna-Maria Kivivuori, Riitta Karikoski, Pirkko Koukila-Kähkölä, Veli-Jukka Anttila, Ulla M. Saarinen-Pihkala. (2011) Zygomycosis Presenting a Major Clinical Challenge: Case Report on Rhizomucor pusillus Infection in a Stem-Cell-Transplant Recipient. Mycopathologia 172:3, 241-245
CrossRef13
John R Perfect. (2011) Azoles: back to the future. Current Opinion in Infectious Diseases 24, S41-S58
CrossRef14
Morena Caira, Enrico Maria Trecarichi, Mario Mancinelli, Giuseppe Leone, Livio Pagano. (2011) Uncommon mold infections in hematological patients: epidemiology, diagnosis and treatment. Expert Review of Anti-infective Therapy 9:7, 881-892
CrossRef15
Erica A. Peterson, Alina S. Gerrie, Maryse M. Power, Micheal P. Poulin, Bakul I. Dalal, Donna L. Forrest. (2011) Disseminated mucormycosis presenting as transplant-associated thrombotic microangiopathy. Leukemia Research 35:7, e138-e140
CrossRef16
E. Ramírez, J. García-Rodríguez, A. M. Borobia, J. M. Ortega, S. Lei, A. Barrios-Fernández, M. Sánchez, A. J. Carcas, A. Herrero, J. M. Puente, J. Frías. (2011) Use of antifungal agents in pediatric and adult high-risk areas. European Journal of Clinical Microbiology & Infectious Diseases
CrossRef17
Thomas R. Rogers, Monica A. Slavin, J. Peter Donnelly. (2011) Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?. British Journal of Haematology 153:6, 681-697
CrossRef18
Hsin-Yun Sun, Nina Singh. (2011) Mucormycosis: its contemporary face and management strategies. The Lancet Infectious Diseases 11:4, 301-311
CrossRef19
Shingo Yano, Jiro Minami, Kaichi Nishiwaki, Takaki Shimada, Nobuaki Dobashi, Yuichi Yahagi, Yutaka Takei, Shinobu Takahara, Yoji Ogasawara, Katsuki Sugiyama, Yuko Yamaguchi, Takeshi Saito, Kinuyo Kasama, Hiroki Yokoyama, Tomohito Machishima, Atsushi Katsube, Noriko Usui, Keisuke Aiba. (2011) Rapid progression and unusual premortal diagnosis of mucormycosis in patients with hematologic malignancies: analysis of eight patients. International Journal of Hematology 93:3, 344-350
CrossRef20
P. Chandrasekar. (2011) Management of invasive fungal infections: a role for polyenes. Journal of Antimicrobial Chemotherapy 66:3, 457-465
CrossRef21
Kristen P. Hook, Lawrence F. Eichenfield. (2011) Approach to the neonate with ecchymoses and crusts. Dermatologic Therapy 24:2, 240-248
CrossRef22
Anna K. Person, Dimitrios P. Kontoyiannis, Barbara D. Alexander. (2011) Fungal Infections in Transplant and Oncology Patients. Hematology/Oncology Clinics of North America 25:1, 193-213
CrossRef23
Herman A. Carneiro, Jeffrey J. Coleman, Alejandro Restrepo, Eleftherios Mylonakis. (2011) Fusarium Infection in Lung Transplant Patients. Medicine 90:1, 69-80
CrossRef24
J. R. Wingard, S. L. Carter, T. J. Walsh, J. Kurtzberg, T. N. Small, L. R. Baden, I. D. Gersten, A. M. Mendizabal, H. L. Leather, D. L. Confer, R. T. Maziarz, E. A. Stadtmauer, J. Bolanos-Meade, J. Brown, J. F. DiPersio, M. Boeckh, K. A. Marr, . (2010) Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 116:24, 5111-5118
CrossRef25
Nikolaos G Almyroudis, Brahm H Segal. (2010) Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients. Expert Review of Anti-infective Therapy 8:12, 1451-1466
CrossRef26
Brad Spellberg, Ashraf S. Ibrahim. (2010) Recent Advances in the Treatment of Mucormycosis. Current Infectious Disease Reports 12:6, 423-429
CrossRef27
Toshikazu Yamazaki, Yukiko Inagaki, Toshihiko Fujii, Jun Ohwada, Masao Tsukazaki, Isao Umeda, Kazuko Kobayashi, Nobuo Shimma, Malcolm G.P. Page, Mikio Arisawa. (2010) In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan. International Journal of Antimicrobial Agents 36:4, 324-331
CrossRef28
Sarah P. Hammond, Francisco M. Marty, Julie M. Bryar, Daniel J. DeAngelo, Lindsey R. Baden. (2010) Invasive fungal disease in patients treated for newly diagnosed acute leukemia. American Journal of Hematology 85:9, 695-699
CrossRef29
T. Aoki, K. Kamezaki, T. Miyamoto, K. Nagafuji, Y. Mori, T. Yamauchi, K. Takenaka, H. Iwasaki, N. Harada, N. Shimono, T. Teshima, K. Akashi. (2010) Cord blood stem cell transplantation in a patient with disseminated mucormycosis and acute myelogenous leukemia. Transplant Infectious Disease 12:3, 277-279
CrossRef30
Anna K. Person, Dimitrios P. Kontoyiannis, Barbara D. Alexander. (2010) Fungal Infections in Transplant and Oncology Patients. Infectious Disease Clinics of North America 24:2, 439-459
CrossRef31
S. Mousset, G. Bug, W.J. Heinz, K. Tintelnot, V. Rickerts. (2010) Breakthrough zygomycosis on posaconazole prophylaxis after allogeneic stem cell transplantation. Transplant Infectious Disease 12:3, 261-264
CrossRef32
M. Leithauser, C. Kahl, C. Aepinus, F. Prall, M. Maruschke, H. Riemer, D. Wolff, K. Jost, I. Hilgendorf, M. Freund, C. Junghanss. (2010) Invasive zygomycosis in patients with graft-versus-host disease after allogeneic stem cell transplantation. Transplant Infectious Disease 12:3, 251-257
CrossRef33
Brian L. Swick, Sindhura C. Reddy, Amanda Friedrichs, Mary Seabury Stone. (2010) Disseminated Scopulariopsis -culture is required to distinguish from other disseminated mould infections. Journal of Cutaneous Pathology 37:6, 687-691
CrossRef34
Richard H. Drew, Mary L. Townsend. (2010) Antifungal Drug Resistance: Clinical Relevance and Impact of Antifungal Drug Use. Current Fungal Infection Reports 4:2, 129-136
CrossRef35
Shmuel Shoham, Shelley S. Magill, William G. Merz, Corina Gonzalez, Nita Seibel, Wendy L. Buchanan, Tena A. Knudsen, Tatyana A. Sarkisova, Thomas J. Walsh. (2010) Primary treatment of zygomycosis with liposomal amphotericin B: analysis of 28 cases. Medical Mycology 48:3, 511-517
CrossRef36
Pranatharthi Chandrasekar. (2010) Diagnostic challenges and recent advances in the early management of invasive fungal infections. European Journal of Haematology 84:4, 281-290
CrossRef37
V. Saegeman, J. Maertens, N. Ectors, W. Meersseman, K. Lagrou. (2010) Epidemiology of mucormycosis: review of 18 cases in a tertiary care hospital. Medical Mycology 48:2, 245-254
CrossRef38
Oliver A. Cornely. (2010) Current Controversies in Treating Invasive Zygomycosis. Journal of Pediatric Hematology/Oncology 32:2, 83-84
CrossRef39
Michael A. Pfaller, Daniel J. Diekema. (2010) Epidemiology of Invasive Mycoses in North America. Critical Reviews in Microbiology 36:1, 1-53
CrossRef40
B. M. Kubak, S. S. Huprikar, . (2009) Emerging & Rare Fungal Infections in Solid Organ Transplant Recipients. American Journal of Transplantation 9, S208-S226
CrossRef41
Michael D. Nailor, Pranatharthi H. Chandrasekar. (2009) Treatment of breakthrough fungal infections: Is there one best drug strategy?. Current Fungal Infection Reports 3:4, 229-235
CrossRef42
Dorothy McCoy, Daryl D DePestel, Peggy L Carver. (2009) Primary Antifungal Prophylaxis in Adult Hematopoietic Stem Cell Transplant Recipients: Current Therapeutic Concepts. Pharmacotherapy 29:11, 1306-1325
CrossRef43
E. Mantadakis, G. Samonis. (2009) Clinical presentation of zygomycosis. Clinical Microbiology and Infection 15, 15-20
CrossRef44
G. N. Pongas, R. E. Lewis, G. Samonis, D. P. Kontoyiannis. (2009) Voriconazole-associated zygomycosis: a significant consequence of evolving antifungal prophylaxis and immunosuppression practices?. Clinical Microbiology and Infection 15, 93-97
CrossRef45
M. Cuenca-Estrella, L. Bernal-Martinez, G. Isla, A. Gomez-Lopez, L. Alcazar-Fuoli, M. J. Buitrago. (2009) Incidence of zygomycosis in transplant recipients. Clinical Microbiology and Infection 15, 37-40
CrossRef46
F. Lanternier, O. Lortholary. (2009) Zygomycosis and diabetes mellitus. Clinical Microbiology and Infection 15, 21-25
CrossRef47
G. L. Petrikkos. (2009) Lipid formulations of amphotericin B as first-line treatment of zygomycosis. Clinical Microbiology and Infection 15, 87-92
CrossRef48
J. F. Meis, A. Chakrabarti. (2009) Changing epidemiology of an emerging infection: zygomycosis. Clinical Microbiology and Infection 15, 10-14
CrossRef49
Livio Pagano, Caterina G. Valentini, Morena Caira, Luana Fianchi. (2009) ZYGOMYCOSIS: Current approaches to management of patients with haematological malignancies. British Journal of Haematology 146:6, 597-606
CrossRef50
Hana Hakim, Patricia M. Flynn, Katherine M. Knapp, Deo Kumar Srivastava, Aditya H. Gaur. (2009) Etiology and Clinical Course of Febrile Neutropenia in Children With Cancer. Journal of Pediatric Hematology/Oncology 31:9, 623-629
CrossRef51
John W. Hiemenz. (2009) Management of Infections Complicating Allogeneic Hematopoietic Stem Cell Transplantation. Seminars in Hematology 46:3, 289-312
CrossRef52
Jane A Cecil, Richard P Wenzel. (2009) Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections. Expert Review of Hematology 2:3, 237-254
CrossRef53
Stefan Weiler, Cornelia Lass-Flörl, Jutta Auberger, Rosa Bellmann-Weiler, Markus Stein, Michael Joannidis, Romuald Bellmann. (2009) Triazole-resistant candidaemia following posaconazole exposure. International Journal of Antimicrobial Agents 33:5, 494-495
CrossRef54
Kei Suzuki, Yumiko Sugawara, Takao Sekine, Kazunori Nakase, Naoyuki Katayama. (2009) Breakthrough disseminated zygomycosis induced massive gastrointestinal bleeding in a patient with acute myeloid leukemia receiving micafungin. Journal of Infection and Chemotherapy 15:1, 42-45
CrossRef55
Pranatharthi Chandrasekar. (2009) Invasive mold infections: recent advances in management approaches. Leukemia & Lymphoma 50:5, 703-715
CrossRef56
Ashraf S. Ibrahim, John E. Edwards, Richard Bryant, Brad Spellberg. (2009) Economic burden of mucormycosis in the United States: can a vaccine be cost-effective?. Medical Mycology 47:6, 592-600
CrossRef57
J.J. Castón-Osorio, A. Rivero, J. Torre-Cisneros. (2008) Epidemiology of invasive fungal infection. International Journal of Antimicrobial Agents 32, S103-S109
CrossRef58
F Schlemmer, M Lagrange-Xélot, C Lacroix, R de La Tour, G Socié, J-M Molina. (2008) Breakthrough Rhizopus infection on posaconazole prophylaxis following allogeneic stem cell transplantation. Bone Marrow Transplantation 42:8, 551-552
CrossRef59
Sébastien Hochart, Frédérique Barrier, Isabelle Durand-Joly, Sandrine Horrent, Bertrand Decaudin, Pascal Odou. (2008) Les antifongiques systémiques Partie 2 : éléments thérapeutiques. Le Pharmacien Hospitalier 43:174, 155-168
CrossRef60
Georgios Chamilos, Russell E. Lewis, Dimitrios P. Kontoyiannis. (2008) Delaying Amphotericin B–Based Frontline Therapy Significantly Increases Mortality among Patients with Hematologic Malignancy Who Have Zygomycosis. Clinical Infectious Diseases 47:4, 503-509
CrossRef61
Kieren A Marr. (2008) Primary antifungal prophylaxis in hematopoietic stem cell transplant recipients: clinical implications of recent studies. Current Opinion in Infectious Diseases 21:4, 409-414
CrossRef62
Pranatharthi Chandrasekar, Per T. Ljungman. (2008) Antifungal Therapy Strategies in Hematopoietic Stem-Cell Transplant Recipients: Early Treatment Options for Improving Outcomes. Transplantation 86:2, 183-191
CrossRef63
K. A. Thursky, E. G. Playford, J. F. Seymour, T. C. Sorrell, D. H. Ellis, S. D. Guy, N. Gilroy, J. Chu, D. R. Shaw. (2008) Recommendations for the treatment of established fungal infections. Internal Medicine Journal 38:6b, 496-520
CrossRef64
M. A. Slavin, C. H. Heath, K. A. Thursky, C. O. Morrissey, J. Szer, L. M. Ling, S. T. Milliken, A. P. Grigg. (2008) Antifungal prophylaxis in adult stem cell transplantation and haematological malignancy. Internal Medicine Journal 38:6b, 468-476
CrossRef65
Fernanda P Silveira, Shahid Husain. (2008) Fungal infections in lung transplant recipients. Current Opinion in Pulmonary Medicine 14:3, 211-218
CrossRef66
Tamás Papp, Ildikó Nyilasi, Árpád Csernetics, László Galgóczy, Csaba Vágvölgyi. (2008) Molecular studies on zygomycetes fungi causing opportunistic infections. Reviews in Medical Microbiology 19:2, 39-46
CrossRef67
Maria Simitsopoulou, Emmanuel Roilides, Avgi Maloukou, Cristina Gil-Lamaignere, Thomas J. Walsh. (2008) Interaction of amphotericin B lipid formulations and triazoles with human polymorphonuclear leucocytes for antifungal activity against Zygomycetes. Mycoses 51:2, 147-154
CrossRef68
Shelley S Magill, Tom M Chiller, David W Warnock. (2008) Evolving strategies in the management of aspergillosis. Expert Opinion on Pharmacotherapy 9:2, 193-209
CrossRef69
Suganthini Krishnan-Natesan, Pranatharthi H Chandrasekar. (2008) Current and Future Therapeutic Options in the Management of Invasive Aspergillosis. Drugs 68:3, 265-282
CrossRef70
M. Torres-Narbona, J. Guinea, J. Martínez-Alarcón, P. Muñoz, T. Peláez, E. Bouza. (2008) Workload and clinical significance of the isolation of zygomycetes in a tertiary general hospital. Medical Mycology 46:3, 225-230
CrossRef71
Carol A. Kauffman, Anurag N. Malani. (2007) Zygomycosis: An emerging fungal infection with new options for management. Current Infectious Disease Reports 9:6, 435-440
CrossRef72
R. J. Trof, A. Beishuizen, Y. J. Debets-Ossenkopp, A. R. J. Girbes, A. B. J. Groeneveld. (2007) Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients. Intensive Care Medicine 33:10, 1694-1703
CrossRef73
S.Y.C. Tong, A.Y. Peleg, J. Yoong, R. Handke, J. Szer, M. Slavin. (2007) Breakthrough Scedosporium prolificans infection while receiving voriconazole prophylaxis in an allogeneic stem cell transplant recipient. Transplant Infectious Disease 9:3, 241-243
CrossRef74
S Trifilio, S Singhal, S Williams, O Frankfurt, L Gordon, A Evens, J Winter, M Tallman, J Pi, J Mehta. (2007) Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplantation 40:5, 451-456
CrossRef75
Shane M. Devlin, Bing Hu, Andrew Ippoliti. (2007) Mucormycosis Presenting as Recurrent Gastric Perforation in a Patient with Crohn’s Disease on Glucocorticoid, 6-Mercaptopurine, and Infliximab Therapy. Digestive Diseases and Sciences 52:9, 2078-2081
CrossRef76
J. Michael Collaco, W. Adam Gower, Peter J. Mogayzel. (2007) Pulmonary dysfunction in pediatric hematopoietic stem cell transplant patients: Overview, diagnostic considerations, and infectious complications. Pediatric Blood & Cancer 49:2, 117-126
CrossRef77
David N. Fredricks. 2007. Molecular Mycology and Emerging Fungal Pathogens. , 375-394.
CrossRef78
Juan José Castón Osorio, Antonio Rivero Román, Julián Torre-Cisneros. (2007) Espectro y factores de riesgo de la infección fúngica invasora. Enfermedades Infecciosas y Microbiología Clínica 25:7, 467-476
CrossRef79
Carol A. Kauffman. 2007. Pearls in Establishing a Clinical Diagnosis: Signs and Symptoms. , 1-18.
CrossRef80
Fernanda P. Silveira, Flavio Queiroz-Telles, Marcio Nucci. 2007. Invasive Mold Infections. , 171-220.
CrossRef81
K. Mullane, A.A. Toor, C. Kalnicky, T. Rodriguez, J. Klein, P. Stiff. (2007) Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections. Transplant Infectious Disease 9:2, 89-96
CrossRef82
S. Padmanabhan, M. Battiwalla, T. Hahn, D. Ball, P. Paplham, K. Brown, B.H. Segal, P. McCarthy, N.G. Almyroudis. (2007) Two cases of hepatic zygomycosis in allogeneic stem cell transplant recipients and review of literature. Transplant Infectious Disease 9:2, 148-152
CrossRef83
Douglas S Kwon, Eleftherios Mylonakis. (2007) Posaconazole: a new broad-spectrum antifungal agent. Expert Opinion on Pharmacotherapy 8:8, 1167-1178
CrossRef84
C Ustun, S Farrow, D DeRemer, H Fain, A P Jillella. (2007) Early fatal Rhizopus infection on voriconazole prophylaxis following allogeneic stem cell transplantation. Bone Marrow Transplantation 39:12, 807-808
CrossRef85
(2007) Posaconazole Prophylaxis in Hematologic Cancer. New England Journal of Medicine 356:21, 2214-2218
Full Text86
Andreas Glöckner, Jörg J. Vehreschild, Oliver A. Cornely. (2007) Zygomycosis ? current epidemiological aspects. Mycoses 50:s1, 50-55
CrossRef87
S M Trifilio, C L Bennett, P R Yarnold, J M McKoy, J Parada, J Mehta, G Chamilos, F Palella, L Kennedy, K Mullane, M S Tallman, A Evens, M H Scheetz, W Blum, D P Kontoyiannis. (2007) Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplantation 39:7, 425-429
CrossRef88
John R. Wingard. (2007) New approaches to invasive fungal infections in acute leukemia and hematopoietic stem cell transplant patients. Best Practice & Research Clinical Haematology 20:1, 99-107
CrossRef89
B. H. Segal, N. G. Almyroudis, M. Battiwalla, R. Herbrecht, J. R. Perfect, T. J. Walsh, J. R. Wingard. (2007) Prevention and Early Treatment of Invasive Fungal Infection in Patients with Cancer and Neutropenia and in Stem Cell Transplant Recipients in the Era of Newer Broad-Spectrum Antifungal Agents and Diagnostic Adjuncts. Clinical Infectious Diseases 44:3, 402-409
CrossRef90
Georgios Chamilos, Russell E. Lewis, Dimitrios P. Kontoyiannis. (2007) Multidrug-resistant endosymbiotic bacteria account for the emergence of zygomycosis: A hypothesis. Fungal Genetics and Biology 44:2, 88-92
CrossRef91
Anurag N Malani, Carol A Kauffman. (2007) Changing Epidemiology of Rare Mould Infections. Drugs 67:13, 1803-1812
CrossRef92
Fernanda P. Silveira, Shahid Husain. (2007) Fungal infections in solid organ transplantation. Medical Mycology 45:4, 305-320
CrossRef93
Joshua Perlroth, Bryan Choi, Brad Spellberg. (2007) Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Medical Mycology 45:4, 321-346
CrossRef94
E. Righi, C. G. Giacomazzi, M. Bassetti, F. Bisio, O. Soro, J. L. McDermott, O. E. Varnier, S. Ratto, C. Viscoli. (2007) Soft-tissue infection with Absidia corymbifera and kidney complications in an AIDS patient. Medical Mycology 45:7, 637-640
CrossRef95
Andrew L. Gilman, Amy Serrano, John Skelley, David Zwick. (2006) Successful treatment of pulmonary zygomycosis with posaconazole in a recipient of a haploidentical donor stem cell transplant. Pediatric Blood & Cancer 47:7, 959-963
CrossRef96
M. A. Sanz Alonso, I. Jarque Ramos, M. Salavert Lletí, J. Pemán. (2006) Epidemiology of invasive fungal infections due to Aspergillus spp. and Zygomycetes. Clinical Microbiology and Infection 12:s7, 2-6
CrossRef97
E. Bouza, P. Muñoz, J. Guinea. (2006) Mucormycosis: an emerging disease?. Clinical Microbiology and Infection 12:s7, 7-23
CrossRef98
J. M. Cisneros Herreros, E. Cordero Matía. (2006) Therapeutic armamentarium against systemic fungal infections. Clinical Microbiology and Infection 12:s7, 53-64
CrossRef99
N. G. Almyroudis, D. P. Kontoyiannis, K. A. Sepkowitz, B. E. DePauw, T. J. Walsh, B. H. Segal. (2006) Issues Related to the Design and Interpretation of Clinical Trials of Salvage Therapy for Invasive Mold Infection. Clinical Infectious Diseases 43:11, 1449-1455
CrossRef100
S. Husain, D. L. Paterson, S. Studer, J. Pilewski, M. Crespo, D. Zaldonis, K. Shutt, D. L. Pakstis, A. Zeevi, B. Johnson, E. J. Kwak, K. R. McCurry. (2006) Voriconazole Prophylaxis in Lung Transplant Recipients. American Journal of Transplantation 6:12, 3008-3016
CrossRef101
Andrew J Ullmann, Oliver A Cornely. (2006) Antifungal prophylaxis for invasive mycoses in high risk patients. Current Opinion in Infectious Diseases 19:6, 571-576
CrossRef102
Jan Jansen, Luke P. Akard, Matthew F. Wack, James M. Thompson, Michael J. Dugan, Jill K. Leslie, Reid Mattison. (2006) Delayed ABLC prophylaxis after allogeneic stem-cell transplantation. Mycoses 49:5, 397-404
CrossRef103
Helen L. Leather, John R. Wingard. (2006) New strategies of antifungal therapy in hematopoietic stem cell transplant recipients and patients with hematological malignancies. Blood Reviews 20:5, 267-287
CrossRef104
Monique A.S.H. Mennink-Kersten, Paul E. Verweij. (2006) Non–Culture-Based Diagnostics for Opportunistic Fungi. Infectious Disease Clinics of North America 20:3, 711-727
CrossRef105
David Andes. (2006) Pharmacokinetics and Pharmacodynamics of Antifungals. Infectious Disease Clinics of North America 20:3, 679-697
CrossRef106
M. A. Pfaller, P. G. Pappas, J. R. Wingard. (2006) Invasive Fungal Pathogens: Current Epidemiological Trends. Clinical Infectious Diseases 43:Supplement 1, S3-S14
CrossRef107
Subroto Paul, Francisco M. Marty, Yolonda L. Colson. (2006) Treatment of Cavitary Pulmonary Zygomycosis With Surgical Resection and Posaconazole. The Annals of Thoracic Surgery 82:1, 338-340
CrossRef108
Gregory T. Siwek, Michael A. Pfaller, Philip M. Polgreen, Sandra Cobb, Peter Hoth, Margarida Magalheas-Silverman, Daniel J. Diekema. (2006) Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. Diagnostic Microbiology and Infectious Disease 55:3, 209-212
CrossRef109
George Aperis, Eleftherios Mylonakis. (2006) Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opinion on Investigational Drugs 15:6, 579-602
CrossRef110
Lynne Strasfeld, David M Weinstock. (2006) Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents. Expert Review of Anti-infective Therapy 4:3, 457-468
CrossRef111
Enrico Schalk, Martin Mohren, Kathleen Jentsch-Ullrich, Frank Dombrowski, Astrid Franke, Michael Koenigsmann. (2006) Zygomycoses in patients with acute leukaemia. Annals of Hematology 85:5, 327-332
CrossRef112
Javier Pem
n, Miguel Salavert, Emilia Cant
CrossRef113
M. Chayakulkeeree, M. A. Ghannoum, J. R. Perfect. (2006) Zygomycosis: the re-emerging fungal infection. European Journal of Clinical Microbiology & Infectious Diseases 25:4, 215-229
CrossRef114
B.D. Alexander, E.S. Dodds Ashley, R.M. Addison, J.A. Alspaugh, N.J. Chao, J.R. Perfect. (2006) Non-comparative evaluation of the safety of aerosolized amphotericin B lipid complex in patients undergoing allogeneic hematopoietic stem cell transplantation. Transplant Infectious Disease 8:1, 13-20
CrossRef115
C. Orla Morrissey, Monica A. Slavin. (2006) Antifungal strategies for managing invasive aspergillosis: The prospects for a pre-emptive treatment strategy. Medical Mycology 44:s1, 333-348
CrossRef116
V. Rickerts, G. Just-Nübling, F. Konrad, J. Kern, E. Lambrecht, A. Böhme, V. Jacobi, R. Bialek. (2006) Diagnosis of invasive aspergillosis and mucormycosis in immunocompromised patients by seminested PCR assay of tissue samples. European Journal of Clinical Microbiology & Infectious Diseases 25:1, 8-13
CrossRef117
Jin Yu, Ruo Yu Li. (2006) Primary renal zygomycosis due to Rhizopus oryzae. Medical Mycology 44:5, 461-466
CrossRef118
Arunaloke Chakrabarti, Ashim Das, Jharna Mandal, M. R. Shivaprakash, Varghese K. George, Bansidhar Tarai, Pooja Rao, Naresh Panda, Subhash C. Verma, Vinay Sakhuja. (2006) The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Medical Mycology 44:4, 335-342
CrossRef119
Sylvia F. Costa, Barbara D. Alexander. (2005) Non-Aspergillus Fungal Pneumonia in Transplant Recipients. Clinics in Chest Medicine 26:4, 675-690
CrossRef120
R. A. Weinstein, S. K. Fridkin. (2005) The Changing Face of Fungal Infections in Health Care Settings. Clinical Infectious Diseases 41:10, 1455-1460
CrossRef121
Lindsey R. Baden, Robert H. Rubin. (2005) Darwinian competition and the pathogenesis of opportunistic infection in the transplant recipient*. Transplant International 18:11, 1223-1225
CrossRef122
Livio Pagano, Beate Gleissner, Luana Fianchi. (2005) Breakthrough Zygomycosis and Voriconazole. The Journal of Infectious Diseases 192:8, 1496-1497
CrossRef123
Livio Pagano, Morena Caira, Paolo Falcucci, Luana Fianchi. (2005) Fungal CNS infections in patients with hematologic malignancy. Expert Review of Anti-infective Therapy 3:5, 775-785
CrossRef124
Thomas F Patterson. (2005) Advances and challenges in management of invasive mycoses. The Lancet 366:9490, 1013-1025
CrossRef125
Perry M. Stevens, Evan J. Anderson, Michelle J. Naidich, Frank H. Miller, Gary A. Noskin. (2005) Sinusitis, Periorbital Edema, and Ocular Proptosis. Infectious Diseases in Clinical Practice 13:5, 255-260
CrossRef126
M. M. Roden, T. E. Zaoutis, W. L. Buchanan, T. A. Knudsen, T. A. Sarkisova, R. L. Schaufele, M. Sein, T. Sein, C. C. Chiou, J. H. Chu, D. P. Kontoyiannis, T. J. Walsh. (2005) Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases. Clinical Infectious Diseases 41:5, 634-653
CrossRef127
M. Nucci, K. A. Marr. (2005) Emerging Fungal Diseases. Clinical Infectious Diseases 41:4, 521-526
CrossRef128
S R Doffman, S G Agrawal, Jeremy S Brown. (2005) Invasive pulmonary aspergillosis. Expert Review of Anti-infective Therapy 3:4, 613-627
CrossRef129
Jacques Bille, Oscar Marchetti, Thierry Calandra. (2005) Changing face of health-care associated fungal infections. Current Opinion in Infectious Diseases 18:4, 314-319
CrossRef130
Gianna Zuccotti, Lynne Strasfeld, David M Weinstock. (2005) New agents for the prevention of opportunistic infections in haematopoietic stem cell transplant recipients. Expert Opinion on Pharmacotherapy 6:10, 1669-1679
CrossRef131
A. Echo, R.V. Hovsepian, G.K. Shen. (2005) Localized cecal zygomycosis following renal transplantation. Transplant Infectious Disease 7:2, 68-70
CrossRef132
John R. Perfect. (2005) Treatment of Non‐ Aspergillus Moulds in Immunocompromised Patients, with Amphotericin B Lipid Complex. Clinical Infectious Diseases 40:S6, S401-S408
CrossRef133
Laura Cudillo, Corrado Girmenia, Stefania Santilli, Alessandra Picardi, Teresa Dentamaro, Andrea Tendas, Paolo de Fabritiis. (2005) Breakthrough Fusariosis in a Patient with Acute Lymphoblastic Leukemia Receiving Voriconazole Prophylaxis. Clinical Infectious Diseases 40:8, 1212-1213
CrossRef134
Nicole Ritz, Roland A. Ammann, Carmen Casaulta Aebischer, Mathias Gugger, Katia Jaton, Ralph A. Schmid, Christoph Aebi. (2005) Failure of voriconazole to cure disseminated zygomycosis in an immunocompromised child. European Journal of Pediatrics 164:4, 231-235
CrossRef135
Meinolf Karthaus, Oliver A. Cornely. (2005) Recent developments in the management of invasive fungal infections in patients with hematological malignancies. Annals of Hematology 84:4, 207-216
CrossRef136
Frauke Mattner, Iris F. Chaberny, H. Weissbrodt, S. Fischer, P. Gastmeier, B. Haubitz, J. Gottlieb, L. Mattner, Martin Strueber. (2005) Surveillance invasiver Fadenpilzmykosen in lungentransplantierten Patienten: Effekt antimykotischer Prophylaxe mit Itraconazol und Voriconazol. Surveillance of invasive mold infections in lung transplant recipients: effect of antimycotic prophylaxis with itraconazole and voriconazole. Mycoses 48:s1, 51-55
CrossRef137
John R Wingard. (2005) The changing face of invasive fungal infections in hematopoietic cell transplant recipients. Current Opinion in Oncology 17:2, 89-92
CrossRef138
S. Vigouroux, O. Morin, P. Moreau, F. Mechinaud, N. Morineau, B. Mahe, P. Chevallier, T. Guillaume, V. Dubruille, J.-L. Harousseau, N. Milpied. (2005) Zygomycosis after Prolonged Use of Voriconazole in Immunocompromised Patients with Hematologic Disease: Attention Required. Clinical Infectious Diseases 40:4, e35-e37
CrossRef139
Charalampos Antachopoulos, Thomas J Walsh. (2005) New agents for invasive mycoses in children. Current Opinion in Pediatrics 17:1, 78-87
CrossRef140
Kirk M. Chan-Tack, Lucia L. Nemoy, Eli N. Perencevich. (2005) Central venous catheter-associated fungemia secondary to mucormycosis. Scandinavian Journal of Infectious Diseases 37:11-12, 925-927
CrossRef141
J. R. Perfect. (2005) Nuances of new anti- Aspergillus antifungals. Medical Mycology 43:s1, 271-276
CrossRef142
Priya Venkatesan, John R. Perfect, Sarah A. Myers. (2005) Evaluation and management of Fungal infections in Immunocompromised patients. Dermatologic Therapy 18:1, 44-57
CrossRef143
E. J. Bow. (2005) Long-term antifungal prophylaxis in high-risk hematopoietic stem cell transplant recipients. Medical Mycology 43:s1, 277-287
CrossRef144
P. H. Chandrasekar. (2005) Antifungal resistance in Aspergillus. Medical Mycology 43:s1, 295-298
CrossRef145
Richard N Greenberg, Lauren J Scott, Heather H Vaughn, Julie A Ribes. (2004) Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Current Opinion in Infectious Diseases 17:6, 517-525
CrossRef146
A. Imhof, S. A. Balajee, D. N. Fredricks, J. A. Englund, K. A. Marr. (2004) Breakthrough Fungal Infections in Stem Cell Transplant Recipients Receiving Voriconazole. Clinical Infectious Diseases 39:5, 743-746
CrossRef147
L. Ide, I. Buysschaert, H. Demuynck, R. De Man, A. Verlinde, E. De Laere, I. Surmont. (2004) Zygomycosis in neutropenic patients with past Aspergillus infection: a role for posaconazole?. Clinical Microbiology and Infection 10:9, 862-863
CrossRef148
G. T. Siwek, K. J. Dodgson, M.-S. de Margarida, L. A. Bartelt, S. B. Kilborn, P. L. Hoth, D. J. Diekema, M. A. Pfaller. (2004) Invasive Zygomycosis in Hematopoietic Stem Cell Transplant Recipients Receiving Voriconazole Prophylaxis. Clinical Infectious Diseases 39:4, 584-587
CrossRef149
C. A. Kauffman. (2004) Zygomycosis: Reemergence of an Old Pathogen. Clinical Infectious Diseases 39:4, 588-590
CrossRef150
Janice MY Brown. (2004) Fungal infections in bone marrow transplant patients. Current Opinion in Infectious Diseases 17:4, 347-352
CrossRef151
Helen W Boucher, Andreas H Groll, Christine C Chiou, Thomas J Walsh. (2004) Newer Systemic Antifungal Agents. Drugs 64:18, 1997-2020
CrossRef152
Nicolas Blin, Nadine Morineau, Fanny Gaillard, Odile Morin, Noël Milpied, Jean-Luc Harousseau, Philippe Moreau. (2004) Disseminated mucormycosis associated with invasive pulmonary aspergillosis in a patient treated for post-transplant high-grade non-Hodgkin's lymphoma. Leukemia & Lymphoma 45:10, 2161-2163
CrossRef
